Continuous Bioprocessing Market: Market Size & Forecast 2026

Continuous bioprocessing connects upstream perfusion bioreactors with downstream purification, filtration, and chromatography steps in a steady, closed-loop flow, replacing the discrete batches that dominate legacy biologics manufacturing. The market is worth about $484.0 billion in 2025 and is forecast to grow at roughly 8.87% annually through the end of the decade. Published estimates vary widely because the segment is being redefined as integrated, multi-step platforms replace earlier single-unit definitions.

• •Global market value: ~$484.0 billion in 2025, with an 8.87% CAGR.
• •Core offering: connected upstream and downstream unit operations producing mAbs, vaccines, biosimilars, and cell/gene therapies.
• •Key benefit set: higher productivity, smaller facilities, lower cost-of-goods, and faster scale-up versus batch.

Demand for cost-effective, scalable biologics manufacturing is the central driver, as pipelines expand in oncology, autoimmune disease, infectious disease, and advanced therapies. AI-driven process control, perfusion media, single-use technologies, and stricter regulatory expectations around consistency are pushing manufacturers toward continuous operations. Post-pandemic pressure to localize vaccine and biologic supply is also accelerating capital investment.

• •Rising biologics and biosimilar pipelines, particularly monoclonal antibodies and mRNA-based vaccines.
• •AI and PAT-enabled process analytics for real-time control and yield optimization.
• •Capital investment in regional, resilient manufacturing capacity, including in North America, Europe, and Asia-Pacific.

The market splits into upstream systems (perfusion bioreactors, cell culture media, cell lines), downstream systems (continuous chromatography, tangential flow filtration, polishing), and integrated end-to-end platforms, with therapeutic applications spanning mAbs, vaccines, recombinant proteins, and cell and gene therapies. North America leads adoption because of its concentrated biopharma manufacturing base and FDA support for process intensification, while Europe is a close second. Asia-Pacific is the fastest-growing region, led by capacity expansion in China, India, South Korea, and Singapore.

• •Workflow split: upstream, downstream, and integrated continuous platforms; mAbs are the largest application.
• •Regional leadership: North America and Europe dominate installed capacity; Asia-Pacific is the fastest-growing region.
• •End-users: large biopharma manufacturers, CDMOs, and academic or government biomanufacturing centers.

What are the recent trends and outlook?

Near-term growth is being shaped by AI-integrated process control, expansion of perfusion-based upstream processes, and broader regulatory acceptance of real-time release and continuous validation. End-to-end, closed and automated platforms are replacing earlier single-unit pilots, with hybrid facilities combining batch and continuous steps during transition. Through the late 2020s and into the 2030s, adoption is expected to broaden from mAbs and vaccines into cell and gene therapies and personalized biologics.

• •Trend 1: AI, PAT, and digital twins used for real-time monitoring, predictive control, and quality-by-design.
• •Trend 2: shift from pilot single-unit deployments to fully integrated, end-to-end continuous facilities.
• •Trend 3: rising use in cell and gene therapy, mRNA, and personalized biologic manufacturing as scale-up matures.